NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT03991130 2025-02-06High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell CarcinomaUniversity of California, San DiegoPhase 2 Terminated6 enrolled
NCT03549000 2024-12-13A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated127 enrolled
NCT03207867 2024-10-09A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaNovartisPhase 2 Terminated315 enrolled 73 charts
NCT02608268 2023-12-06Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Terminated252 enrolled 67 charts